Table 2. Treatment.
| Type | No. (%) | Duration in days, median (range) |
|---|---|---|
| Amoebicidal agents | ||
| Chlorhexidine 0.02% | 219 (97.8) | 175 (14–881) |
| As monotherapy | 32 | |
| Unknown | 2 | 13 |
| Brolene® 1% | 183 (81.7) | 88.5 (5–881) |
| As monotherapy | 1 | |
| Unknown | 3 | 10 |
| PHMB 0.02% | 6 (2.7) | 104 (32–263) |
| As monotherapy | 2 | |
| Unknown | 3 | 0 |
| Additional medical therapy | ||
| Antibiotics | 156 (69.6) | 63.5 (1–819) |
| Unknown | 3 | 31 |
| Antifungals | 126 (56.3) | 43.5 (1–572) |
| Unknown | 1 | 19 |
| Corticosteroids (after diagnosis) | 91 (40.6) | 217 (5–1780) |
| Unknown | 3 | 25 |
| Duration between diagnosis and start | 36 (0–708) | |
| Unknown | 6 | |
| Maximal pain management | data unavailable | |
| None | 90 (40.2) | |
| Paracetamol | 23 (10.3) | |
| NSAIDs | 41 (18.3) | |
| Opioids | 51 (22.8) | |
| Unknown | 19 (8.5) | |
| Surgical therapy | not applicable | |
| Acute intervention | ||
| Keratoplasty | 49 (21.9) | |
| Enucleation | 1 (0.4) | |
| Unknown | 2 (0.9) | |
| Secondary intervention | ||
| Keratoplasty | 32 (14.3) | |
| Evisceration | 2 (0.9) | |
| Unknown | 1 (0.4) | |
| Cataract surgery | 32 (14.3) | |
| Not applicable | 5 (2.2) | |
| Unknown | 26 (11.6) |